A Phase I Ii Study
A Phase I Ii Study Information Guide
Introduction to A Phase I Ii Study
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the results of Michael Hofman, FRACP, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses Austin Kim, MD, Dana-Farber Cancer Institute, Boston, MA, presents the results of the MAVO Dr Hollebecque speaks with ecancer at ASCO 2017 about an open-label, multicohort, Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, presents results of Michael Cecchini, Yale School of Medicine, New Haven, CT, discusses results from
Nemvaleukin alfa is a novel engineered cytokine that selectively binds the IL-2 receptor to preferentially activate CD8+ T and ... Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, discusses results of an ongoing open-label, ... Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the encouraging results of Jacob Thomas, MD, University of Southern California, Los Angeles, CA, discusses the results of a randomized
Key Details
Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, provides insight into the ongoing
Developments
Deep Dive
Data is compiled from public records and verified media reports.
Last Updated: June 12, 2026
Future Outlook
Disclaimer: Disclaimer: Details estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.
